



UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 29 2011

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 5,795,865. Please note that the Applicant, Dyax Corp., has also applied for patent term extension for U.S. Patent No. 7,276,480 (Docket No.: FDA-2010-E-0334) for the regulatory review period of BLA No. 125277/0 pursuant to the provisions of 37 C.F.R. § 1.785. The application was filed on January 11, 2010, under 35 U.S.C. § 156. The application was filed on January 11, 2010, under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Laurie Butler Lawrence
Lando & Anastasi, LLP
One Main Street
Cambridge, MA 02142

RE: KALBITOR® (ecallantide)
Docket No. FDA-2010-E-0333